Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

RBC Capital has initiated coverage of Dyne Therapeutics (NASDAQ:DYN) and Avidity Biosciences (NASDAQ:RNA) with outperform ...

WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with ...

Investing.com -- Shares of Dyne Therapeutics (NASDAQ:DYN) climbed 3.9% following the announcement that the European Commission has granted orphan drug designation to the company’s lead product ...

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases ...

Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...